Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This pilot early phase I trial studies the side effects of temozolomide, radiation therapy,
and tumor treating fields therapy using Novo tumor treatment fields (TTF)-200A device in
participants with glioblastoma. Drugs used in chemotherapy, such as temozolomide, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Radiation therapy uses high energy
x-rays to kill tumor cells and shrink tumors. NovoTTF-200A device is a portable device that
produces alternating electrical fields that may disrupt growth of cancer cells. Giving
temozolomide, radiation therapy, and tumor treating fields therapy using NovoTTF-200A device
may work better in treating participants with glioblastoma.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University